Niagen Bioscience, Inc. (NAGE)

In the past six months, Niagen Bioscience launched the Niagen Skincare Innovation Lab and debuted Niagen NanoCloud™, launched Tru Niagen® Beauty, and expanded the availability of Niagen Plus™ products to over 50 iCRYO clinics. The company reported a 30% year-over-year net sales increase to $129.4 million and a 103% net income increase to $17.4 million in 2025. The company increased its share repurchase program to $20 million and surpassed 300 external research agreements on Niagen®. ChromaDex Corporation changed its name to Niagen Bioscience, Inc. and began trading under the symbol "NAGE". NAGE shares hit a 52-week high of $14.69 and a 52-week low of $4.16 in the last year.

The provided information does not explicitly detail demand seasonality for Niagen Bioscience, Inc. products and services. However, the company notes that demand for its portfolio of longevity solutions continues to increase as awareness of the benefits of NAD+ becomes mainstream.

Niagen Bioscience, Inc. (NAGE), formerly ChromaDex Corporation, is a bioscience company focused on developing healthy aging products. Headquartered in Los Angeles, the company operates in the Biotechnology industry, advancing NAD+ science and healthy-aging research. It operates through three segments: Consumer products, Ingredients, and Analytical Reference Standards and Services. Its flagship ingredient is Niagen®, a patented nicotinamide riboside (NR). Major products include Tru Niagen®, Niagen® Plus, Niagen® (Ingredient), Analytical Reference Standards and Services, Tru Niagen® Beauty, and Niagen NanoCloud™.

Niagen Bioscience, Inc. is headquartered in Los Angeles, California, and distributes its Tru Niagen® products in the United States. Its pharmaceutical-grade Niagen IV and injections are available at over 1,200 clinics nationwide. The company describes itself as a global bioscience company with a patent portfolio protecting NR and other NAD+ precursors worldwide.

Niagen Bioscience positions itself as a global authority in NAD+ discoveries, dedicated to advancing healthspan through science and NAD+-boosting solutions. The company emphasizes its investment in research, partnerships with institutions like the National Institutes of Health, and its robust patent portfolio. Niagen Bioscience also stresses its commitment to scientific rigor, safety, quality, and transparency. The launch of new products and expansion of Niagen IV availability suggest ongoing innovation and market presence.

Niagen Bioscience is publicly traded on the NASDAQ. Robert N. Fried serves as the Chief Executive Officer and Director, and Frank Louis Jaksch is the Co-Founder & Chairman.